KnightSwan Acquisition Corporation (NYSE:KNSW) (the "Company"), a publicly-traded special purpose acquisition company, today announced that its board of directors (the "Board") has determined to redeem all of its
https://www.qualcomm.com/news/onq/2023/10/introducing-our-next-gen-intelligent-pc-platforms-the-snapdragon-x-series Qualcomm Technologies has been pushing the boundaries of innovation in powering consumer and
Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20
SAN DIEGO, July 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage